WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2025)
Top general drug manufacturer stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...
OverviewZen RatingPriceValue
GrowthFinancialsMomentumSentimentForecastDividendsDue Diligence
A
General Drug Manufacturers is Zen Rated A and is the 5th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Zen Rating
Price
Value
Graham Fair Value
Graham Fair Value %
P/E
Forward P/E
P/S
P/B
PEG
Free Cash Flow
Free Cash Flow Yield
Book Value
BVPS
EV
EV/EBITDA
NVS
NOVARTIS AG
$121.02$68.2677.29%18.79x13.71x4.47x6.18x1.32x$17.70B7.43%$38.37B19.50$261.32B9.89
JNJ
JOHNSON & JOHNSON
$156.90$79.7096.87%17.32x14.75x4.23x4.83x1.88x$20.37B5.39%$78.11B32.45$391.29B11.28
GRFS
GRIFOLS SA
$9.74$11.65-16.39%38.05x10.15x0.84x1.02x0.34x$357.52M5.34%$6.54B9.51$16.90B9.87
GILD
GILEAD SCIENCES INC
$109.64$67.3162.90%22.99x13.81x4.75x7.12x0.95x$9.84B7.21%$19.16B15.38$153.41B14.50
GSK
GSK PLC
$38.28$36.365.29%18.82x8.68x1.89x4.20x0.54x$7.17B9.16%$18.63B9.11$96.62B15.69
AMGN
AMGEN INC
$295.27$163.7780.30%26.72x14.18x4.65x25.58x1.02x$10.92B6.87%$6.21B11.54$207.34B13.57
BMY
BRISTOL MYERS SQUIBB CO
$46.86$42.4810.30%17.49x7.04x2.00x5.48x0.60x$13.09B13.72%$17.39B8.55$134.20B9.47
AZN
ASTRAZENECA PLC
$71.13$41.4571.59%28.40x15.87x3.22x5.37x0.91x$11.16B5.06%$41.04B13.24$246.92B13.97
ABBV
ABBVIE INC
$192.45$86.36122.86%81.55x15.98x5.93x239.40x0.93x$15.39B4.52%$1.42B0.80$404.66B28.30
PFE
PFIZER INC
$25.65$23.0211.44%18.45x8.42x2.33x1.61x0.59x$11.22B7.71%$90.34B15.92$206.51B14.47
SNY
SANOFI
$48.61$38.2826.98%21.02x10.72x2.64x1.52x0.68x$7.65B6.29%$80.74B32.26$133.70B11.24
LLY
ELI LILLY & CO
$793.01$272.11191.43%64.26x36.17x14.54x47.67x1.38x$3.74B0.52%$15.76B17.54$786.99B51.01
SCLX
SCILEX HOLDING CO
$6.46N/AN/A-0.46x-0.26x1.47x-0.21xN/AN/AN/A-$211.48M-18.29$87.92M-1.33
BIIB
BIOGEN INC
$134.21$112.2719.54%13.21x8.98x2.00x1.16x0.85x$2.38B12.16%$16.98B116.21$23.69B9.39
MRK
MERCK & CO INC
$83.36$76.379.15%12.10x9.39x3.29x4.33x0.77x$17.04B8.10%$48.34B19.16$235.53B9.04
OGN
ORGANON & CO
$9.94$30.85-67.78%3.42x2.67x0.41x4.77x0.24x$781.00M30.47%$542.00M2.10$10.99B7.42
AMRN
AMARIN CORP PLC
$16.93N/AN/A-3.85x-7.38x1.63x0.74xN/A-$30.88M-8.82%$473.69M22.92$238.69M-3.03
MIRA
MIRA PHARMACEUTICALS INC
$1.28N/AN/A-2.51x-2.91xN/A16.73xN/A-$6.14M-28.83%$1.29M0.08$20.45M-2.55
1

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Novartis Ag (NYSE:NVS)


Novartis Ag (NYSE:NVS) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Novartis Ag (NYSE:NVS) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: B, and AI: B.

Novartis Ag (NYSE:NVS) has a Due Diligence Score of 34, which is -10 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates NVS as a "A".

NVS passed 12 out of 38 due diligence checks and has average fundamentals. Novartis Ag has seen its stock return 9.52% over the past year, overperforming other general drug manufacturer stocks by 22 percentage points.

2. Johnson & Johnson (NYSE:JNJ)


Johnson & Johnson (NYSE:JNJ) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Johnson & Johnson (NYSE:JNJ) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Johnson & Johnson (NYSE:JNJ) has a Due Diligence Score of 51, which is 7 points higher than the general drug manufacturer industry average of 44.

JNJ passed 18 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 4.81% over the past year, overperforming other general drug manufacturer stocks by 18 percentage points.

Johnson & Johnson has an average 1 year price target of $163.80, an upside of 4.4% from Johnson & Johnson's current stock price of $156.90.

Johnson & Johnson stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Johnson & Johnson, 10% have issued a Strong Buy rating, 20% have issued a Buy, 70% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: C, and AI: B.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 32, which is -12 points lower than the general drug manufacturer industry average of 44. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 10.06% over the past year, overperforming other general drug manufacturer stocks by 23 percentage points.

Grifols Sa has an average 1 year price target of $10.30, an upside of 5.75% from Grifols Sa's current stock price of $9.74.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) has an annual dividend yield of 5.84%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.35%.

Organon & Co's dividend payout ratio of 38.5% indicates that its high dividend yield is sustainable for the long-term.

2. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) has an annual dividend yield of 4.95%, which is 2 percentage points higher than the general drug manufacturer industry average of 3.35%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 121.6% indicates that its high dividend yield might not be sustainable for the long-term.

3. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.55%, which is 1 percentage points higher than the general drug manufacturer industry average of 3.35%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 88.1% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.94% in the last day, and up 1.72% over the last week. Gilead Sciences was the among the top losers in the drug manufacturers - general industry, dropping -4.28% yesterday.

Shares of drug stocks are trading lower after the FDA reportedly indicated it could fast track drugs to companies that cut US prices in line with other countries.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 27 points higher than the general drug manufacturer industry average of 44. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -52.39% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -40 percentage points.

2. Merck & Co (NYSE:MRK)


Merck & Co (NYSE:MRK) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Merck & Co has a valuation score of 57, which is 13 points higher than the general drug manufacturer industry average of 44. It passed 4 out of 7 valuation due diligence checks.

Merck & Co's stock has dropped -35.36% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -23 percentage points.

3. Biogen (NASDAQ:BIIB)


Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 42 points higher than the general drug manufacturer industry average of 44. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has dropped -43.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -31 percentage points.

Are general drug manufacturer stocks a good buy now?

42.86% of general drug manufacturer stocks rated by analysts are a hold right now. On average, analysts expect general drug manufacturer stocks to rise by 50.62% over the next year.

16.67% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 33.33% of general drug manufacturer stocks are rated B (Buy), 44.44% are rated C (Hold), 0% are rated D (Sell), and 5.56% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 38.63x.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.